JP4641941B2 - トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法 - Google Patents

トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法 Download PDF

Info

Publication number
JP4641941B2
JP4641941B2 JP2005507102A JP2005507102A JP4641941B2 JP 4641941 B2 JP4641941 B2 JP 4641941B2 JP 2005507102 A JP2005507102 A JP 2005507102A JP 2005507102 A JP2005507102 A JP 2005507102A JP 4641941 B2 JP4641941 B2 JP 4641941B2
Authority
JP
Japan
Prior art keywords
compound
solution
product
bis
epothilone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2005507102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006510743A (ja
JP2006510743A5 (enExample
Inventor
ヨン リー，
カート サンダーマン，
リー タング，
ディビット マイレス，
Original Assignee
コーサン バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーサン バイオサイエンシーズ， インコーポレイテッド filed Critical コーサン バイオサイエンシーズ， インコーポレイテッド
Publication of JP2006510743A publication Critical patent/JP2006510743A/ja
Publication of JP2006510743A5 publication Critical patent/JP2006510743A5/ja
Application granted granted Critical
Publication of JP4641941B2 publication Critical patent/JP4641941B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2005507102A 2002-11-07 2003-11-07 トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法 Expired - Fee Related JP4641941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42535202P 2002-11-07 2002-11-07
US47374303P 2003-05-27 2003-05-27
PCT/US2003/035411 WO2004043954A2 (en) 2002-11-07 2003-11-07 Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010228356A Division JP5679757B2 (ja) 2002-11-07 2010-10-08 トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法

Publications (3)

Publication Number Publication Date
JP2006510743A JP2006510743A (ja) 2006-03-30
JP2006510743A5 JP2006510743A5 (enExample) 2006-12-21
JP4641941B2 true JP4641941B2 (ja) 2011-03-02

Family

ID=32314587

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2005507102A Expired - Fee Related JP4641941B2 (ja) 2002-11-07 2003-11-07 トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法
JP2010228356A Expired - Fee Related JP5679757B2 (ja) 2002-11-07 2010-10-08 トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法
JP2013147528A Pending JP2013213054A (ja) 2002-11-07 2013-07-16 トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010228356A Expired - Fee Related JP5679757B2 (ja) 2002-11-07 2010-10-08 トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法
JP2013147528A Pending JP2013213054A (ja) 2002-11-07 2013-07-16 トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法

Country Status (14)

Country Link
US (2) US20040152708A1 (enExample)
EP (3) EP2135867B1 (enExample)
JP (3) JP4641941B2 (enExample)
KR (2) KR100996996B1 (enExample)
AT (1) ATE452888T1 (enExample)
AU (1) AU2003291337B2 (enExample)
CA (1) CA2505368C (enExample)
CY (1) CY1110295T1 (enExample)
DE (1) DE60330703D1 (enExample)
DK (1) DK1562941T3 (enExample)
ES (2) ES2436296T3 (enExample)
PT (1) PT1562941E (enExample)
SI (1) SI1562941T1 (enExample)
WO (1) WO2004043954A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2135867B1 (en) * 2002-11-07 2013-09-25 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same
CN1330648C (zh) * 2002-11-07 2007-08-08 科桑生物科学公司 反式－9,10－脱氢埃坡霉素c和d,其类似物以及制备这些化合物的方法
US20050002983A1 (en) * 2003-03-28 2005-01-06 Johnson Robert G. Devices, methods, and compositions to prevent restenosis
KR20060122819A (ko) * 2003-10-09 2006-11-30 코산 바이오사이언시즈, 인코포레이티드 치료학적 제형
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2678941C (en) 2007-02-23 2018-11-27 Aileron Therapeutics, Inc. Triazole macrocycle systems
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
WO2008141234A2 (en) * 2007-05-11 2008-11-20 Kosan Biosciences Incorporated Methods of making epothilones
US8030503B2 (en) 2007-05-11 2011-10-04 Kosan Biosciences Incorporated Process for the preparation of epothilones
BRPI1006139A2 (pt) 2009-01-14 2017-05-30 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2011038049A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
KR20180058866A (ko) 2010-08-13 2018-06-01 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
CA2776178A1 (en) * 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329073T2 (de) 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
AU6833994A (en) 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
PT1052974E (pt) 1998-02-05 2009-08-07 Novartis Ag Formulação farmacêutica contendo epotilona
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19907480A1 (de) * 1999-02-11 2000-08-17 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954229A1 (de) * 1999-11-04 2001-05-10 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
JP2003500368A (ja) 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル
GB9918429D0 (en) 1999-08-04 1999-10-06 Novartis Ag Organic compounds
KR100832145B1 (ko) 2000-04-28 2008-05-27 코산 바이오사이언시즈, 인코포레이티드 폴리케타이드의 제조방법
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
WO2003022844A2 (en) * 2001-09-06 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones intermediates thereto and analogues thereof
EP2186811A1 (en) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2135867B1 (en) * 2002-11-07 2013-09-25 Kosan Biosciences Incorporated Trans-9, 10-dehydroepothilone C and trans-9, 10-dehydroepothilone D, analogs thereof and methods of making the same

Also Published As

Publication number Publication date
JP2006510743A (ja) 2006-03-30
ES2436296T3 (es) 2013-12-30
DK1562941T3 (da) 2010-04-19
CY1110295T1 (el) 2015-01-14
KR20100018075A (ko) 2010-02-16
EP2135868A1 (en) 2009-12-23
EP2135867A1 (en) 2009-12-23
SI1562941T1 (sl) 2010-05-31
CA2505368A1 (en) 2004-05-27
JP5679757B2 (ja) 2015-03-04
EP1562941B1 (en) 2009-12-23
JP2013213054A (ja) 2013-10-17
ES2336911T3 (es) 2010-04-19
WO2004043954A3 (en) 2004-11-18
DE60330703D1 (de) 2010-02-04
PT1562941E (pt) 2010-01-25
AU2003291337A1 (en) 2004-06-03
EP2135867B1 (en) 2013-09-25
EP1562941A2 (en) 2005-08-17
US20040152708A1 (en) 2004-08-05
KR100966667B1 (ko) 2010-06-29
KR20050084959A (ko) 2005-08-29
US20090186927A1 (en) 2009-07-23
CA2505368C (en) 2011-09-20
AU2003291337B2 (en) 2010-09-09
JP2011006480A (ja) 2011-01-13
KR100996996B1 (ko) 2010-11-25
WO2004043954A2 (en) 2004-05-27
ATE452888T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
JP5679757B2 (ja) トランス−９，１０−デヒドロエポチロンｃおよびｄ、それらのアナログ、ならびにそれらを作製する方法
JP2006510743A5 (enExample)
US20020045609A1 (en) Epothilone derivatives and methods for making and using the same
US6489314B1 (en) Epothilone derivatives and methods for making and using the same
US6596875B2 (en) Method for synthesizing epothilones and epothilone analogs
US6893859B2 (en) Epothilone derivatives and methods for making and using the same
US20020156110A1 (en) Epothilone compounds and methods for making and using the same
WO2002080846A2 (en) Epothilone derivatives and methods for making and using the same
JP2009007367A (ja) シクロプロピルおよびシクロブチルエポチロンアナログ
KR20010102199A (ko) Ｃ-21 변형 에포틸론
JP2004500388A (ja) エポチロン、その中間体およびその類似体の合成
US20030023082A1 (en) Epothilone derivatives and methods for making and using the same
US7070964B2 (en) Epothilone compounds and methods for making the same
US20030134883A1 (en) 14-Methyl-epothilones
JP2004518728A (ja) ラウリマリド誘導体
CN1330648C (zh) 反式－9,10－脱氢埃坡霉素c和d,其类似物以及制备这些化合物的方法
JP2006511483A (ja) ２’’オキソ−ボルウスカリンおよびその誘導体
US20070203346A1 (en) Method for synthesizing epothilones and epothilone analogs

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061106

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081217

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100514

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101008

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101130

R150 Certificate of patent or registration of utility model

Ref document number: 4641941

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131210

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees